Screener
Eli Lilly LLY Acquired in-process research and development
Discontinued — last reported Q1 '26
Acquired in-process research and development at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Eli Lilly in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff.
The source filing: Eli Lilly’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 11:25 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000059478-26-000045
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Cost of sales | 3,577 | 2,225 |
| Research and development | 3,510 | 2,734 |
| Marketing, selling, and administrative | 2,934 | 2,468 |
| Acquired in-process research and development | 584 | 1,572 |
| Asset impairment, restructuring, and other special charges | 279 | 35 |
| Other–net, (income) expense | 65 | 239 |
| 10,949 | 9,273 | |
| Income before income taxes | 8,850 | 3,456 |
Item 1. Financial Statements
FAQ
- What is Eli Lilly's acquired in-process research and development?
- Eli Lilly (LLY) reported acquired in-process research and development of $584M in Q1 2026.
- How has Eli Lilly's acquired in-process research and development changed year-over-year?
- Eli Lilly's acquired in-process research and development decreased by 62.8% year-over-year, from $1.57B to $584M.
- What is the long-term trend for Eli Lilly's acquired in-process research and development?
- Over 4 years (2021 to 2025), Eli Lilly's acquired in-process research and development has grown at a 31.6% compound annual growth rate (CAGR), from $970.1M to $2.91B.
- What does acquired in-process research and development mean?
- This metric captures the costs associated with acquiring research and development projects from third parties that have not yet reached technological feasibility. These are often one-time charges related to strategic acquisitions or licensing deals designed to bolster the R&D pipeline. It represents a form of externalized innovation investment.
Ask your AI about Eli Lilly's acquired in-process research and development.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude